Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPN-100 in hepatic encephalopathy
NCT00999167Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium phenylbutyrate in hepatic encephalopathy (HE), sponsored by Amgen. Started Dec 2009; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT00999167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00999167.